Psoriasiform exfoliative erythroderma induced by golimumab

Psoriasiform exfoliative erythroderma induced by golimumab

Summary Golimumab is a fully human anti‐tumour necrosis factor (TNF)‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐TNF drugs is well documented, but to our knowledge, th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental dermatology 2014-10, Vol.39 (7), p.813-815
Hauptverfasser: Mateo, S., García-Martínez, F. J., Sánchez-Aguilar, D., Amarelo, J., Toribio, J.
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal - adverse effects
Dermatitis, Exfoliative - chemically induced
Humans
Male
Middle Aged
Pharmaceutical industry
Psoriasis
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Golimumab is a fully human anti‐tumour necrosis factor (TNF)‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.
ISSN:0307-6938
1365-2230
DOI:10.1111/ced.12402